Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA‐associated vasculitis: A case report

Abstract Avacopan, a C5a receptor antagonist (C5aR) presents a new therapeutic option to improve outcomes in ANCA‐associated vasculitis (AAV). Here we present a case report of a patient initially requiring kidney replacement therapy (KRT), where avacopan was added as an additional adjunctive therapeutic agent late in the treatment course.